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Abstract: In the western world, colorectal cancer (CRC) is the third most common cause of
cancer-related deaths. Survival is closely related to the stage of cancer at diagnosis striking the clinical
need for biomarkers capable of early detection. To search for possible biological parameters for early
diagnosis of CRC we evaluated protein expression for three CREC (acronym: Cab45, reticulocalbin,
ERC-55, calumenin) proteins: reticulocalbin, calumenin, and ERC-55 in a cellular model consisting of
a normal derived colon mucosa cell line, NCM460, and a primary adenocarcinoma cell line of the
colon, SW480. Furthermore, this cellular model was analyzed by a top-down proteomic approach,
2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and liquid chromatography–tandem
mass spectrometry (LC–MS/MS) for novel putative diagnostic markers by identification of differentially
expressed proteins between the two cell lines. A different colorectal carcinoma cell line, HCT 116,
was used in a bottom-up proteomic approach with label-free quantification (LFQ) LC–MS/MS. The two
cellular models gave sets of putative diagnostic CRC biomarkers. Various of these novel putative
markers were verified with increased expression in CRC patient neoplastic tissue compared to the
expression in a non-involved part of the colon, including reticulocalbin, calumenin, S100A6 and
protein SET. Characterization of these novel identified biological features for CRC patients may have
diagnostic potential and therapeutic relevance in this malignancy characterized by a still unmet
clinical need.
Keywords: colorectal adenocarcinoma; colorectal cancer; protein expression; proteomics; biomarkers;
cellular model system
1. Introduction
Colorectal cancer (CRC) is among the leading causes of death in the Western countries and
considerable effort are spent identifying diagnostic biomarkers. Mean overall survival is closely related
Int. J. Mol. Sci. 2020, 21, 3466; doi:10.3390/ijms21103466 www.mdpi.com/journal/ijms
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to the stage at time of diagnosis. The 5-year overall survival rates are around 50% [1–3]. In the western
world, CRC is the third most common cause of cancer deaths, striking the clinical need for biomarkers
able to identify the malignancy at an early stage of cancer [4].
Molecular genetic analyses have revealed numerous mutations underlying the pathogenesis
of CRC. However, most identified mutations seem only to be present in subsets of the patients
and only well-known suppressor genes, e.g., p53, APC, and KRAS are mutated in the majority of
patients [5]. Several factors may influence the proteomic machinery and affect the final properties of the
encoded protein at several levels: translational inhibition/activation, posttranslational modifications,
inhibition/activation of the proteins, specific degradations, etc. Consequently, there can be considerable
discrepancy between the expression level of RNA and that of the corresponding protein product [6].
Proteins are the molecules that execute most cellular functions and many regulatory processes take
place at the protein level. Furthermore, the majority of all current therapies are directed at proteins.
This prompted us to analyze putative CRC diagnostic markers at the protein level.
In recent years, extensive research has intended to identify biomarkers for CRC in blood and stool
but in spite of this, these markers are still of limited clinical value. Furthermore, large population-based
programs have been established to screen for CRC [7]. The screening programs are primarily based on
fecal test for blood. However, in Western cultures, handling has reduced the compliance to programs.
In contrast, the collection of a blood sample is usually more acceptable for the general population.
Consequently, search for both genetic and non-genetic markers has increased during the last decades.
The only biomarker so far used in clinical practice is carcinoembryonic antigen (CEA), but its value as an
isolated screening and prognostic marker is limited and it is currently recommended as a supplement
approach in monitoring CRC recurrence [8–12].
Protein expression analysis of tissue may be difficult due to the heterogeneous nature with the
presence of a number of different cell types that each may vary in protein expression. A cellular
model system is inherently more homogeneous due to the restricted number of cell types present,
although even a cell type may show some degree of heterogeneity and be sensitive to the conditions
of cultivation. In the present study, we have compared the protein expression of a normal derived
colon mucosa cell line, NCM460 [13] with the expression in two cell lines, one cell line established
from a primary adenocarcinoma of the colon, SW480 [14], and another cell line established from
a human colonic carcinoma, HCT 116 [15]. These model cell culture systems possess a number of
differences [16] and have previously been analyzed for transcript expression [17]. Amongst seven
differentially expressed transcripts, Nimmrich et al. found the transcript of the CREC member
reticulocalbin to be upregulated in the cancer cell line SW480 as compared with the normal-derived
cell line, NCM460 [17]. Several reports have revealed differential expression of the CREC proteins
by studying diseases or model systems such as cancer cells, or cells exposed to various forms of
treatment or “stress” and comparing these with normal conditions [18,19]. We investigated the
protein expression of three CREC proteins which previously have been related to the development of
cancer. Reticulocalbin has been shown to be implicated in breast, non-small cell lung, and hepatic
cancer [20–22]. The transcript expression of calumenin has been shown to be correlated to risk-groups
in mesothelioma and down-regulation has been associated with lung squamous cell carcinomas [23,24].
ERC-55 expression has been shown in correlation to tumor-mass in breast cancer and in more aggressive
forms of cervical cancer together with a study showing downregulation of ERC-55 in regard to prostate
cancer [25–27]. We investigated the potential of reticulocalbin, calumenin and ERC-55 as diagnostic
markers, initially in the SW480 cellular model and then for two of them in confirmatory analyses with
CRC patient tissue samples from: (i) the central part of the tumor and (ii) the peripheral part of the
tumor as well as (iii) a tumor free part of the colon.
Furthermore, we identify new putative protein markers for diagnostic use in CRC by proteomic
comparison of the expression levels in two different cellular models and found numerous differentially
expressed proteins. The expression patterns of selected identified proteins, i.e., S100A4, S100A6,
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retinol-binding protein I (RBP), Protein SET, and endoplasmin (HSP90B1) were further evaluated in
the cell lines and/or in CRC patient tissue by western blotting.
2. Results
2.1. CREC Protein Expression in NCM460 and SW480 Cell Lines and in Patient Colorectal Cancer
(CRC) Tissue
We have compared the protein expression of three members of the CREC family reticulocalbin,
calumenin and ERC-55 in a CRC cellular model, i.e., a normal derived colon mucosa (NCM460) cell line
and a cell line established from a primary adenocarcinoma of the colon (SW480) [13,14]. Reticulocalbin
and calumenin are both highly increased at the protein level in the cancer cell line (p < 0.001, p < 0.01)
(Figure 1A). Moreover, the protein band recognized by the calumenin antibody decreases slightly in
size in the cancer cell line as compared with the normal derived cell line. The third CREC member,
ERC-55, is expressed at similar levels in the normal derived cell line, NCM460, as in the cancer cell
line, SW480.
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Figure 1. Western blotting of three CREC family members. (A) NCM460 and SW480 cells were grown
in separate rounds and harvested prior to total protein concentration determination and equal amounts
of protein were loaded on the gels. Pixel intensity was measured in each band and the mean value
of NCM460 was used as a reference set to 1. p values were calculated with Mann-Whitney U-test.
Relative pixel intensities are depicted at a log2-transformed scale in the dot plots. (B) Colorectal
cancer (C C) patient tissue was collected during bowel resection for CRC. Proteins were solubilized by
homogenization in lysis buff r prior to otal protein conc ntration determinat on and eq al amounts
of protein were loaded o the gels. Pixel intensity was measured in each band and the value of each
non-involved (N) ba d were set to 1 and the peripheral (P) and central (C) samples were calculated
relative to the non-involved tissue value in each patient. p values were calculated with Wilcoxon
signed-rank test. Relative pixel intensities are depicted at a log2-transformed scale in the dot plots.
** p < 0.01; *** p < 0.001.
Subsequently, we analyzed the protein expression of reticulocalbin and calumenin in biopsies
from 10 patients diagnosed with CRC (Table 1). Since ERC-55 was present at similar levels in the two
cell lines we saved the patient biopsies for other putative markers. From each patient a sample was
taken from the central part of the tumor (C), the peripheral part of the tumor (P) as well as from a
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non-involved part of the colon (N). Reticulocalbin is highly expressed in the central part as well as in
the peripheral part of the tumor (p < 0.01, p < 0.001) compared to the expression of the non-involved
part of the colon. A similar pattern is observed for calumenin (p < 0.01, p < 0.01) (Figure 1B).
Table 1. Patient characteristics.
Patient
no. Sex
Age by the Time
of Diagnosis Localization T N M Rt-Type Recurrence
Death Due
to CRC
3 M 63 0 4 2 1 0 NA Y
13 M 73 0 3 1 1 0 NA Y
17 M 58 0 4 2 0 0 Y Y
20 F 75 1 2 0 0 2 N -
25 M 65 0 3 0 0 0 Y -
40 M 69 0 2 0 0 0 N -
46 M 76 0 3 0 0 0 Y -
48 F 80 0 3 0 1 0 NA Y
78 F 54 0 4 1 1 0 NA Y
97 M 79 0 3 0 0 0 N -
Characterization of patients included in the project. Sex: Female(F)/ Male(M), Age by the time of diagnosis: in years,
Localization: of the tumor 0 = colon 1 = rectum, TNM Clinical Classification T = primary tumor 1–4 N = Regional
Lymph Nodes 0–2 M = Distant Metastasis 0–2, Rt-type = Radiotherapy 0–2 (0 = no radiotherapy 1 = long-course
52Gy/26 fractions 2 = Short-course 25Gy/5 fractions) Recurrence: Y = yes N = no NA = not appropriate, Death due
to CRC: Y = yes N= no.
2.2. Top-Down Proteomic Comparison of NCM460 and SW480 Cell Lines
We further analyzed the NCM460/SW480 cellular model system by performing a proteomic
comparison using 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) in order to detect
protein spots that were significantly and at least 2-fold differentially expressed between the two cell lines.
This analysis revealed 73 spots changing in expression. All spots were excised for protein identification.
Twenty-five spots (16 with protein identifications) were upregulated and 48 spots (22 with protein
identifications) were downregulated (Figure 2) in the colon cancer cell line (SW480) compared to the
protein expression of the normal-derived colon cell line (NCM460). In total 38 spots were identified
with at least one peptide by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Details
are given in Table 2.
Table 2. Identification of differentially expressed proteins in SW480 versus NCM460 cells.
Ratio
SW480/
NCM460
SSP Identification Peptides MascotScore Mr (Da) SwissProt Name
0.15 9002 Transgelin-2 2 48 22377 TAGL2_HUMAN
0.15 6204 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase,mitochondrial 1 49 35793 ECH1_HUMAN
0.17 2804
Transitional endoplasmic reticulum ATPase 6 269 89958 TERA_HUMAN
Src substrate protein p85 2 80 63462 SRC8_HUMAN
0.20 4001 Protein S100-A4 2 125 11721 S10A4_HUMAN
0.24 1801 Endoplasmin fragment 9 405 92696 ENPL_HUMAN
0.26 4109 Endoplasmic reticulum protein ERp29 1 75 28975 ERP29_HUMAN
0.27 2902 Hypoxia up-regulated protein 1 11 401 111494 HYOU1_HUMAN
0.28 3601 FK506-binding protein 4 6 366 52057 FKBP4_HUMAN
0.28 3705
Heat shock cognate 71 kDa protein 3 170 70854 HSP7C_HUMAN
Lamin-B2 1 110 67647 MMNB2_HUMAN
Stress-70 protein mitochondrial 3 87 73635 GRP75_HUMAN
0.29 8608 Adenylyl cyclase-associated protein 1 1 46 51823 CAP1_HUMAN
0.33 8701 Heterogeneous nuclear ribonucleoprotein L 3 70 60719 HNRPL_HUMAN
0.35 1501 Tubulin beta 3 229 ca. 50000 TBB2C_HUMAN **
0.38 1002 Thioredoxin 1 52 12015 THIO_HUMAN
0.39 9003 Growth factor receptor-bound protein 2, fragment 3 75 25190 GRB2_HUMAN
0.42 9207 Voltage-dependent anion-selective channel protein 1 1 107 30722 VDAC1_HUMAN
0.42 1603 Tubulin alpha 4 195 ca. 50000 TBA1B_HUMAN **
0.43 5303 60S acidic ribosomal protein P0-like 1 56 34343 RLA0L_HUMAN
0.45 8206
Annexin A2
1 53
38580 ANXA2_HUMAN
Putative annexin A2-like protein 38635 AXA2L_HUMAN
0.46 8204
Annexin A2
2 120
38580 ANXA2_HUMAN
Putative annexin A2-like protein 38635 AXA2L_HUMAN
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Table 2. Cont.
Ratio
SW480/
NCM460
SSP Identification Peptides MascotScore Mr (Da) SwissProt Name
0.46 6603 T-complex protein 1 subunit beta 6 418 57452 TCPB_HUMAN
0.46 6202 Proteasome subunit alpha type-1 2 70 29537 PSA1_HUMAN
0.48 7403 Elongation factor Tu, mitochondrial 1 42 49510 EFTU_HUMAN
2.07 3206 Tubulin alpha, fragment 1 64 ca. 50000 TBA1B_HUMAN **
2.07 0401 Putative heat chock protein HSP 90-beta-3, fragment 1 42 68282 H90B3_HUMAN
2.11 3104 Prohibitin 4 131 29786 PHB_HUMAN
2.14 0301 Nucleophosmin 1 56 32555 NPM_HUMAN
2.16 0304 Protein SET 1 60 33469 SET_HUMAN
2.26 0607 Endoplasmin, fragment 4 170 92411 ENPL_HUMAN
2.76 0101 Acidic leucine-rich nuclear phosphoprotein 32 familymember A 1 89 28568 AN32A_HUMAN
3.17 5003 Vesicle-associated membrane protein-associatedprotein B/C, fragment 4* 156 27211 VAPB_HUMAN
3.28 3202 Tubulin beta, fragment 1 65 ca. 50000 TBB5_HUMAN **
6.08 3002 Cellular retinoic acid-binding protein 2 7* 401 15683 RABP2_HUMAN
6.65 4004 Cofilin-1, fragment 3 158 18507 COF1_HUMAN
8.58 5105 Triosephosphate isomerase 4 274 26698 TPIS_HUMAN
17.94 0008 Nucleophosmin, fragment 1 77 32555 NPM_HUMAN
18.45 3208 ATP-dependent DNA helicase 2 subunit 2, fragment 1 88 82652 XRCC5_HUMAN
99.68 0009 Nucleophosmin, fragment 1 48 32555 NPM_HUMAN
378.64 1007 Retinol-binding protein I, cellular
1 69
15840 RET1_HUMAN3 * 182
4 * 147
* Identified from Coomassie stained gels. The rest is identified from silver stained gels. ** Several variants.
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Figure 2. Proteomic analysis of NCM460 and SW480 using a top-down proteomic strategy.
A representative gel from each group (A) NCM460 and (B) SW480, molecular mass is given in
kDa. NCM460 and SW480 cells were grown in separate rounds and harvested prior to total protein
concentration determination and equal amounts of protein were loaded on the gels. Each group consisted
of 6 samples. Comparative analyses of the spots were done with the PDQuest software. All differentially
identified spots with 2-fold or more increased/decreased expression and with significance level (p < 0.05)
with Mann-Whitney U-test are shown on the representative gels in the figure.
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2.3. Bottom-up Proteomic Comparison of NCM460 and HCT 116 Cell Lines
The NCM460/HCT 116 cellular model system was analyzed by label-free quantification (LFQ)
LC–MS/MS proteomics in order to detect proteins that were significantly and at least 2-fold differentially
expressed in this cellular model system. We found 901 proteins to be differentially expressed,
465 upregulated and 436 downregulated, Figure 3. The differentially expressed proteins are listed
in supplementary Table S1. Retinol-binding protein I was highly upregulated in HCT 116 and was
below detection limit in NCM460 in line with the 2D-PAGE results (Figure 2, spot 1007). None of the
CREC proteins, reticulocalbin, calumenin or ERC-55 were changed in this system. Protein SET and
endoplasmin were not changed either. Only one of the S100 proteins was detected, S100A10, and it
was not changed.
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Figure 3. Proteomic analysis of NCM460 and HCT 116 using a bottom-up proteomic strategy. Proteins
were analyzed by label-free quantification (LFQ) liquid chromatography–tandem mass spectrometry
(LC–MS/MS). MaxQuant and Perseus were used for data analysis. The log2 transformed relative
expression levels of HCT 116 versus NCM460 are plotted on the x-axis and on the y-axis are plotted the
log10 transformed p-values. Unchanged proteins are indicated with grey circles. 901 proteins were
significantly (p < 0.05) at least 2-fold differentially expressed. 777 of these are indicated with black circles
and 57 were detected in all HCT 116 samples and were below detection limit in all NCM460 samples
while 67 proteins were detected in all NCM460 and were below detection limit in all HCT 116 samples.
They could not be pictured in the volcano plot, but are included in supplementary Table S1.
2.4. Immunologic Evaluation of Protein Expression
The expression patterns of a number of the identified differentially expressed proteins obtained
by 2D-PAGE and by LFQ LC–MS/MS were further evaluated by 1D western blotting of the cell lines,
NCM460 and SW480, s well as of tissu from CRC pati nts (Figure 4).
2.5. S100 Proteins
S100A4 (spot 4001) was strongly downregulated in the 2D-PAGE proteomic analysis (Figure 2)
and this was confirmed by the western blot analysis which also showed strong downregulation of the
protein in the SW480 cancer cell line (Figure 4A). This antibody did not show specific reaction in the
patient tissue samples. However, an antibody against another member of the S100 family, S100A6,
showed reasonable specificity in both systems. S100A6 is upregulated in the SW480 cancer cell line
(p < 0.01). In the tissue analysis, we found the protein to be upregulated in the central part of the
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tumor compared to the non-involved part of the colon (p < 0.05) (Figure 4A,B). Only one S100 protein,
S100A10, was detected with LFQ LC–MS/MS and it was unchanged in HCT 116.
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Figure 4. Western blotting of potential markers. (A) NCM460 and SW480 cells were grown in separate
rounds and harvest prior to total protein concentration determination and equal amount of protein
were loaded on the gels. Pixel intensity was measured in each band and the mean value of NCM460 was
used as reference set to 1. Total pixel intensity from the two bands for protein SET showed no significant
difference (p = 0.2). However, quantifying the top band alone showed significant up-regulation in
NCM460 (p < 0.05) whereas the lower band showed no significant difference (p = 0.9). p values were
calculated with Mann-Whitney U-test. Relative pixel intensities are depicted at a log2-transformed scale
in the dot plots. (B) CRC patient tissue was exercised from CRC during resection for CRC. Proteins
were solubilized by homogenization in lysis buffer prior to total protein concentration determination
and equal amounts of protein were loaded on the gels. Pixel intensity was measured in each band and
the value of each non-involved (N) band was set to 1 and the periphery (P) and central (C) samples were
calculated relative to the non-involved value in each patient. p values were calculated with Wilcoxon
signed-rank test. Quantification of protein SET was done on the total expression (all bands together),
the top band alone and the band just below the top band alone which all showed the p-values as stated
in the figure. To save space, the western blot of protein SET has been compressed in the y-direction
as inferred by the range of the molecular masses stated by the marker. Few bands were recognized
by the endoplasmin antibody migrating approximately at 40 and 25 kDa (not shown). Relative pixel
intensities are depicted at a log2-transformed scale in the dot plots. * p < 0.05; ** p < 0.01; *** p < 0.001.
2.6. Retinol-Binding Protein I
The antibody against retinol-binding protein I (Figure 2, spot 1007) reacted strongly with the cancer
cell line revealing strong upregulation compared with the normal derived colon cell line (p < 0.01) in
agreement with the 2D-PAGE proteomic analysis (Figures 2 and 4A and Table 2). Technically, it was not
possible to analyze the tumor tissue due to unspecific reactions of the antibody (not shown). The LFQ
LC–MS/MS proteomic analysis also revealed strong upregulation of this protein in the HCT 116 cell
line, supplementary Table S1.
2.7. Protein SET
Protein SET (Figure 2, spot 0304) was increased in the 2D-PAGE proteomic analysis of SW480. 1D
western blotting of the cell lines revealed two closely migrating bands. The upper band analyzed alone
showed significant decrease in the SW480 cell line (p < 0.05) while the lower band did not show any
significant difference (Figure 4A). When the expression pattern of the protein was analyzed in tumor
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tissue an even more complex pattern was seen since the antibody reacted with several bands on the
western blot suggesting that the protein is fragmented in the non-involved part of colon as well as in
the tumor tissue (Figure 4B). We found that the central part as well as the peripheral part of the tumor
contained significantly more protein/fragments than the non-involved colon (p < 0.001, p < 0.001).
The LFQ LC–MS/MS proteomic analysis revealed an unchanged level in the HCT 116 cell line.
2.8. Endoplasmin
Endoplasmin (Figure 2, spot 1801) with a molecular mass of approximately 80 kDa showed a
significant decrease in the cancerous SW480 cell line in the 2D-PAGE proteomic analysis and the 1D
western blot of the cell lines confirmed the result (p < 0.01) (Figure 4A). The 2D-PAGE proteomic
analysis also revealed a fragment of endonuclein (Figure 2, spot 0607) with a molecular mass of
approximately 55 kDa to be increased in the cancerous cell line. Analysis of the tumor tissue showed a
major band of endoplasmin with a molecular mass of approximately 64 kDa, which was significantly
increased in the peripheral part (p < 0.01) of the tumor but not in the central part compared to the
non-involved part of the colon. Additional minor bands with molecular masses around 40 kDa and
25 kDa were observed in the tissue western blot analyses (not shown). The LFQ LC–MS/MS proteomic
analysis revealed an unchanged level in the HCT 116 cell line.
2.9. Bioinformatic Enrichment Analysis of SW480 versus NCM460
The combined set of perturbed proteins from 2D-PAGE and western blot analysis was used
for bioinformatic analysis using STRING [28] as given in Figure 5. In order to focus on protein
identifications with high reliability we restricted the analysis to proteins identified with at least two
peptides. The perturbed proteins have significantly more interactions than expected (p < 1.84 × 10−11).
Thus, the analysis indicated that the proteins are at least partially biologically related. All the 20 proteins
belong to the ‘cytoplasmic part’ of the Gene Ontology (GO) classification Cellular Component. With
respect to Molecular Function 19 belong to various types of ‘binding’ such as protein binding,
small molecule binding, signaling receptor binding, enzyme binding, purine ribonucleotide binding,
calcium ion binding, RNA binding and cytoskeletal binding as indicated in Figure 5B. Figure 5C
reveals the proteins found to be enriched in Reactome pathways. Eight were found to be part of
‘signal transduction’, eight of ‘metabolism of proteins’, and seven were part of the ‘immune system’.
Thus, proteins found to be perturbed in SW480 were mainly cytoplasmic proteins with various
binding functions that participate in pathways of signal transduction, protein metabolism, and the
immune system.
2.10. Bioinformatic Enrichment Analysis of HCT 116 versus NCM460
The differentially expressed proteins by LFQ LC–MS/MS were analyzed by STRING [28].
The proteins had significantly more interactions (7610 edges) than the expected 5050 (p < 1 × 10−16),
see supplementary Figure S1. The large majority of proteins, 720, belong to the Cellular Component:
‘cytoplasmic part’ whereas 269 belong to the ‘nuclear part’. With Molecular Function ‘binding’ is
substantially represented with 683 proteins involved, specified as ‘protein binding’ (420), ‘ion binding’
(369), ‘organic cyclic compound binding’ (325), ‘heterocyclic compound binding’ (324), ‘small molecule
binding’ (224), and ‘anion binding’ (220). Additionally, several proteins are characterized with ‘catalytic
activity’ (469). Proteins enriched in the Reactome Pathways were ‘metabolism’ (206), ‘metabolism
of proteins ‘(159), ‘immune system’ (133), ‘post-translational protein modification’ (102), and ‘innate
immune system’ (94). Thus, proteins found to be perturbed in HCT 116 were mainly cytoplasmic
proteins with various binding functions, some having catalytic activity, that participate in protein
metabolism and the immune system.
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Figure 5. Bioinformatic analysis of differentially expressed proteins. (A) STRING v11.0 was
used to analyze the genes listed in Table 2 identified with two peptides together with
S100A6, calumenin, and reticulocalbin: TAGLN2 (TAGL2_HUMAN), S100A4 (S10A4_HUMAN),
CALU (CALU_HUMAN), RCN1 (RCN1_HUMAN), RBP1 (RET1_HUMAN), TPI1 (TPIS_HUMAN),
CFL1 (COF1_HUMAN), CRABP2 (RABP2_HUMAN), VAPB (VAPB_HUMAN), HSP90B1
(ENPL_HUMAN), PHB (PHB_HUMAN), PSMA1 (PSA1_HUMAN), CCT2 (TCPB_HUMAN),
TUBA1B (TBA1B_HUMAN), GRB2 (GRB2_HUMAN), TUBB4B (TBB4B_HUMAN—updated
from TBB2C_HUMAN), HNRNPL (HNRPL_HUMAN), FKBP4 (FKBP4_HUMAN), HYOU1
(HYOU1_HUMAN), S100A4 (S10A4_HUMAN). The 20 proteins have 29 interactions which are
significantly more than the expected 6 (p < 1.84 × 10−11). The analysis indicated that the proteins
are at least partially biologically related. (B) The 19 proteins involved in various binding functions
are indicated with color. Red (13 proteins): ‘protein binding’; blue (8 proteins): ‘small molecule
binding’; light green (7 proteins): ‘signaling receptor binding’; pink (7 proteins): ‘enzyme binding’;
yellow (6 proteins): ‘purine ribonucleotide binding’; green (5 proteins): ‘calcium ion binding’; brown
(5 proteins): ‘RNA binding’; light blue (5 proteins): ‘cytoskeletal protein binding’. (C) Proteins identified
to be part of Reactome pathways. Red (8 proteins): ‘signal transduction’; blue (8 proteins): ‘metabolism
of proteins’; green (7 proteins): ‘immune system’.
3. Discussion
A number of studies have been published on diagnostic/prognostic/predictive markers including
hypothesis-generating proteomic analysis of CRC performed with patient samples, animal models
and cell lines as review d by d Wit e al. [29]. In the present study, the s mple material included t
total protein content from cellular models e tablish from a primary adenocarcinoma of the colon,
SW480, a colonic carcinoma, HCT 116, and a normal der ved colon mucosa cell line, NCM460. The two
colorectal cance cell lin s show a number of differences [16]. SW480 from D kes’ B stage tumor
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shows intermediate growth while HCT 116 from a Dukes’ D stage tumor is fast growing. SW480
shows microsatellite stability while HCT 116 possesses microsatellite instability. SW480 and HCT
116 have different CpG island methylator phenotypes and different chromosomal instability status.
Additionally, they show a number of differences in mutations of KRAS (G12V in SW480, G13D in HCT
116), PIK3CA (wt in SW480, H1047R in HCT 116) and TP53 (R273H and P309S in SW480, wt in HCT
116) [16]. In spite of these molecular differences as well as differences in specific proteins that are
differentially expressed, the bioinformatic analyses showed a number of similarities with respect to
enriched pathways among the two cell lines. 2D-PAGE and LFQ LC–MS/MS-based proteomic analyses
have not previously been published with these cellular systems. The biological variation within a cell
line is minimal as compared to patient samples. However, results from model systems show some
differences in expression levels of proteins and must be further verified in patient samples to establish
the clinical impact.
3.1. Model Systems Versus Patient Tissue
In the present analysis, we identified some differentially expressed proteins in one of the cell
models that show similar expression patterns in the patient tissue (reticulocalbin (SW480), calumenin
(SW480), S100A6 (SW480)). Other proteins showed a more complex pattern (protein SET, endoplasmin).
We were unable to establish the expression pattern in the patient tissue for S100A4 and retinol binding
protein I. The latter was highly upregulated in both cell lines, SW480 and HCT 116. The antibodies did
not work on tissue, presumably because the protein composition may be different from the cellular
model systems. Patient tumor tissue may also be heterogeneous and show varying degrees of central
necrosis. Further a tumor may consist of different clones, which may have different protein composition.
Therefore, we analyzed central as well as peripheral parts of the tumor. Thus, conclusions from the
model systems cannot always be transferred to the clinical setting.
3.2. Proteomics Methodology
We have used 2D-PAGE where quantification is performed directly on intact proteins (top-down
proteomics) as well as LFQ LC–MS/MS where quantification is performed on tryptic generated peptides
(bottom-up proteomics). Proteoforms [30] of the proteins can be separated by 2D-PAGE if they
vary in pI and/or molecular mass, which may include different posttranslational modifications and
fragmentations. Since bottom-up proteomics is performed on peptides from digested proteins this
technique does not give detailed information about proteoforms of the proteins. A major advantage
of the latter technique is that it can be performed on formalin-fixed paraffin-embedded (FFPE) CRC
patient tissue [31]. FFPE in combination with 2D-PAGE is still insufficient [32]. The use of frozen tumor
tissue is applicable with 2D-PAGE.
3.3. Comparisons of 2-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) with 1D Western Blotting
When 2D-PAGE is compared with 1D western blotting, there are some issues to be considered.
In order to obtain consistent results, antibody specificity is crucial. The specificity may depend on
the protein composition in the system used, as the combination of proteins may be different from the
cell lines to tissue samples. Here, we report results from the antibodies that worked either in the cell
lines and/or in the tissue. Another problem is that proteins may consist of several proteoforms that
may migrate to different isoelectric points with similar molecular masses using 2D-PAGE. Differential
expression of each of these single isoelectric variants may be detected by proteomic analysis using
2D-PAGE while this may not be apparent when all isoelectric variants are analyzed together as a single
band using 1D western blotting. As an example, triosephosphate isomerase migrates as at least three
proteoforms that vary in isoelectric points but with similar molecular masses that are expressed to
varying degrees in NCM460 and SW480 (Figure 6A). However, the 1D western blot analysis revealed
band intensities that were quite similar in the two cell lines (Figure 6B).
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3.4. Differentially Expressed Proteins
3.4.1. CREC Proteins
We found two of the three CREC proteins analyzed, reticulocalbin and calumenin, to be increased
in the tum r cell line SW480, and both of them w re also expressed to a higher degree in tumor biopsies
(periph ral and central part) both comp red to the non-involved part of th colon. T y were not
changed in th HCT 116 cell li e. ERC-55, nother CREC protein was expressed at similar levels in the
cell model systems of normal derived cells, NCM460, and cancer c lls, SW480 and HCT 116, and was
not furth r xamined. In the c llular model, the olecular masse of calumeni vary b tw en the two
cell lines (SW480 and NCM460) and egarding reticulocalbin more bands are observed in the tis ue
biopsi s. Both of thes expressi n patterns may be due to glycosylations as previously shown for
CREC protein [33–35]. Thus, the differential expressions and differences in putative glycosylation
states of reticulocalbin and calume in imply some role of these proteins in CRC pathogen is.
3.4.2. S100 Proteins
The S100 family consists of more than twenty members with a high degree of sequence and
structural similarities. So far, almost all of the S100 family members are involved in cancer with different
expression patterns. In SW480, S100A4 was downregulated while S100A6 was upregulated. S100A6
was upregulated in the central part of the tumor compared to the non-involved part of the bowel.
This pattern is consistent with previous studies [36–39]. The interpretation of high S100A4 expression is
not unequivocal. Some studies have found a positive [40] where other studies show a negative [41,42]
impact of high S100A6 expression in regard to CRC. The divergent results of S100A4 expression may
be based on not taking the cellular localization into consideration. Previously, it has been shown that
nuclear S100A4 from adenocarcinomas of the colon or rectum is a negative predictor of disease-free
and overall survival whereas cytoplasmic S100A4 was not associated with patient outcome [43]. In the
HCT 116 cell line we only detected S100A10 with LFQ LC–MS/MS and it was unchanged.
3.4.3. Retinol-Binding Protein I
Retinol-binding protein I (RBP) was highly upregulated in SW480 both in the 2D-PAGE proteomic
analysis, with western blotting of the cell lines and also in the HCT 116 cell line by LFQ LC–MS/MS.
However, no specific antibody reaction was obtained on the patient tissue. Previous studies have
shown that low level of RBP is correlated to an increased risk of tumor recurrence [44]. Furthermore,
Ali et al. have shown that upregulation of RBP might have a role in TGF-β/Smad4 signaling resulting in
cancer progression [45]. Thus, the expression pattern of RBP is not fully established. Still, this protein
may be an important player in progression and recurrence in CRC.
Int. J. Mol. Sci. 2020, 21, 3466 12 of 18
3.4.4. Protein SET
Protein SET was differentially expressed in the SW480 cellular model although not in the HCT 116
model. Western blotting of SW480 showed a two-band pattern, likely identifying the α- and β-isoforms
(TAF-1α (290 amino acids)), TAF-1β (277 amino acids)). The two isoforms are 98.7% identical and differs
only in the N-terminal 1-47 amino acids. The top band in SW480 showed significant downregulation.
A complex pattern was found in CRC tissue with several bands. Quantification of all bands together
showed a significant upregulation of protein SET in the peripheral and central part of the tumor
compared to the non-involved part of the colon. Previously, protein SET was found upregulated in
HCT 116 regarding a putative effect in the COX-2 inhibitor celecoxib [46]. The specific role of protein
SET in pathogenesis of CRC awaits further investigations.
3.4.5. Endoplasmin
Endoplasmin was identified in two spots in the 2D-PAGE proteomic analysis of SW480. Spot 1801
(Figure 2, approximately 80 kDa) is downregulated in SW480, and spot 0607 (Figure 2, approximately
55 kDa) is upregulated. Both spots possess lower molecular masses than the deduced mass of
endoplasmin (92.4 kDa). Western blots showed a main band at approximately 80 kDa, most likely
corresponding to spot 1801, that was downregulated in the SW480 cancer cell line confirming the
2D-PAGE analysis. No pronounced bands with lower molecular masses were observed in the SW480
cellular model. In the HCT 116 cellular system endoplasmin showed no changes. CRC patient tissue
showed a major band with a molecular mass of approximately 64 kDa, also lower than the deduced
mass, with a slight but significant up-regulation in the peripheral part of the tumor compared to the
non-involved colon. Additional bands with even lower molecular masses (approximately 40 kDa and
approximately 25 kDa) were also detected in the tumor tissue (not shown). Previously, two studies
have shown endoplasmin expression to be correlated with CRC [47]. Thus, our results together with
these studies infer that the expression of endoplasmin is complex and may correlate with CRC.
3.5. Conclusions
The CREC proteins reticulocalbin and calumenin seem to have a role in CRC carcinogenesis
whereas ERC-55, another family member, shows no differential regulation indicating a specific role of
reticulocalbin and calumenin and not the CREC family as such. Both reticulocalbin and calumenin
were found with high expression in the tumor compared to the healthy part of colon and must therefore
be seen as potential markers of CRC. Furthermore, in this study, more putative markers have been
identified including the S100 protein S100A4 and S100A6, RBP, protein SET, and endoplasmin which
are observed to be differentially regulated either in one of the cellular model systems and/or in CRC
patient tissue. Further studies must be performed to investigate the biological roles of the various
identified putative markers of CRC aiming at elucidating the clinical relevance of these new potential
disease makers.
4. Materials and Methods
4.1. Cell Lines
SW480 (ATCC® CCL-228™), a cell line established from a primary adenocarcinoma of the colon
(Dukes’ type B) and HCT 116 (ATCC® CCL-247™), a cell line established from a male adult with
colorectal carcinoma were obtained from ATCC. NCM460, a cell line derived from normal colon mucosa
was obtained from INCELL Corporation LLC (San Antonio, TX, USA) through a licensing agreement.
The cell lines were cultured in M3:BaseATM (M310A, INCELL Corporation LCC, San Antonio, TX, USA)
enriched with 10% fetal bovine serum (FBS) GibcoTM 10270-098 (Thermo Fisher Scientific, Waltham,
MA, USA) to make M3:10A.
Confluent cells were washed three times in PBS-buffer without Ca2+ and Mg2+ and scraped
off. Pellets were further washed with PBS-buffer and kept at −80 ◦C until use. Cell pellets were
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re-suspended in SDS sample buffer (LC2676, Invitrogen) for 1D western blotting and in 2D lysis
buffer (9M Urea, 2% (vol/vol) Triton X-100, 2% (wt/vol) DTT, 2% (vol/vol) IPG-buffer (GE Healthcare,
Buckinhamshire, UK)) for 2D-PAGE analysis and in lysis buffer (5% (wt/vol) SDS, 50 mM TEAB,
pH 7.55) for LFQ LC–MS/MS analysis. Protein concentration was determined using the Non-Interfering
Protein Assay (488250, Calbiochem®, Merck KGaA, Darmstadt, Germany) or by infrared spectrometry
(Direct Detect Spectrometer, Merck KGaA, Darmstadt, Germany) [48].
4.2. Tissue Biopsies from Patients with CRC
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by The North Denmark Region Committee on Health Research Ethics (Project identification
No. 2-16-4-0001-03) and the Danish data agency. This project was further approved (18 December 2017)
by the National Committee on Health Research Ethics (Project identification No. 60819). Biopsies
were obtained from ten patients with CRC, Table 1. From each patient 3 samples were collected, one
from the central part, one from the peripheral part of the tumor, as well as one from the resection
margin furthest from the tumor. The tissue samples were collected from the tumor and bowel just
after the specimen was removed from the abdomen, rinsed in cold saline, frozen in liquid nitrogen,
and stored at −80 ◦C. For protein extraction, initially, the tissue was rinsed with PBS-buffer if presence
of excess blood was observed, then solubilized in IP 3-10 NL lysis buffer (9M Urea, 2% (vol/vol)
Triton X-100, 2% (wt/vol) DTT, 2% (vol/vol) IPG-buffer (GE Healthcare)) using a homogenizer. Protein
concentration was determined using the Non-Interfering Protein Assay (488250, Calbiochem®, Merck
KGaA, Darmstadt, Germany).
4.3. Two-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE)
2D-PAGE was done essentially as previously described [49]. Six replicates of each cell line were
harvested and from each sample 75 µg of total protein was loaded on the gels. In short, first dimension
isoelectric focusing (IEF) was performed using pH 3–10 nonlinear 18 cm strips (GE Healthcare).
Separation in the second dimension was performed using polyacrylamide gels (12% T, 3% C). Gels
were then silver stained and scanned on a GS-710 Imaging Densitometer (Bio-Rad, Hercules, CA, USA)
using Quantity-One. The TIFF files were then imported into PDQuest software (BioRad, Hercules, CA,
USA). Protein spots were initially automatically defined and quantified and then manually investigated
for proper alignment between the gels. Differentially expressed spots were defined as spots that were
2-fold or more differentially expressed with a significance level at p < 0.05 (Mann-Whitney U-test).
4.4. Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS) for Protein Identification
Differentially expressed spots were excised from either the rehydrated silver stained gels or for a
few spots from Coomassie blue stained gels. The excised spots were subjected to in-gel tryptic digestion
and peptides were identified by liquid chromatography–tandem mass spectrometry (LC–MS/MS) with
a Q-Tof Premier mass spectrometer (Waters, Milford, MA, USA). Proteins were identified by searching
in the SwissProt protein database (various releases from 52.5–57.11) using the online version of the
Mascot MS/MS Ions Search facility (Matrix Science, Ltd., London, UK) [50]. The parameters used for
searching were doubly and triply charged ions with up to two missed cleavages, a peptide tolerance
between 20 and 100 ppm or 1 Da, one variable modification, Carbamidomethyl-C (occasionally together
with oxidation of Met) and a MS/MS tolerance of 0.02 or 0.05. Contaminating peptides such as keratins
and trypsin were disregarded. Individual ions scores above approximately 34–37 indicated identity or
extensive homology giving a less than 5% probability that the observed match was a random event.
4.5. Label-Free Quantification Liquid Chromatography–Tandem Mass Spectrometry (LFQ LC–MS/MS)
Proteomic comparison of cell lines NCM460 with HCT 116 were performed with LFQ LC–MS/MS
using an LC-MS instrument platform from Thermo Fisher Scientific (Waltham, MA, USA). This was
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performed essentially as previously described [51] with slight modifications. Protein preparation and
tryptic digestions from each cell line was performed using the S-Trap Micro Spin Column procedure
(Protifi, Farmingdale, NY, USA) as described by the manufacturer. In short, from each of the cell lines six
20 µg protein preparations were alkylated with TCEP and digested with trypsin. Peptide concentration
was measured by fluorescence as described [48]. Samples were dried by vacuum centrifugation and
dissolved in 0.1% formic acid. Peptides were separated by nano liquid chromatography, Ultimate
3000 (Thermo Fisher Scientific, Waltham, MA, USA). Peptides were trapped with a µ-Precolumn
(300 µm × 5 mm, C18 PepMap100, 5 µm, 100 Å (Thermo Fisher Scientific, Waltham, MA, USA) and
separated on an analytical column (EASY-Spray Column, 500 mm × 75 µm, PepMap RSCL, C18, 2 mm,
100 Å, Thermo Scientific) coupled to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).
Peptides were eluted with a flow of 300 nL/min. using a gradient by mixing buffer A (99.9% (vol/vol)
water, 0.1% (vol/vol) formic acid) with buffer B (99.9% (vol/vol) acetonitrile, 0.1% (vol/vol) formic acid).
One µg of peptide was injected from each preparation in duplicate. The universal method setting was
used with full Orbitrap scans (m/z 375–1500) at a resolution of 120,000 with automatic gain control
(AGC) target of 4 × 105 and a maximum injection time of 50 ms. Most intense precursors were selected
with an intensity threshold of 5 × 103. Charge states 2–7 were included. In the linear ion trap MS2
scans were performed at rapid scan rate with collision-induced dissociation energy at 35%, an AGC
target of 2 × 103 and a maximum injection time of 300 ms. Precursor ions were isolated using the
quadrupole set with an isolation window of 1.6 m/z. Cycle time was 3 s and dynamic exclusion was set
to 60 s. Raw data files were used to search the reviewed human database from Uniprot downloaded on
the 9th of February 2020 and using MaxQuant version 1.6.6.0 for LFQ analysis [52]. Carbamidomethyl
(C) was used as fixed modification. False discovery rate for PSM, protein and identification by site was
each set at 1%. The LFQ minimum ratio count was set to 1. MS/MS was required for LFQ comparisons.
Unique and razor peptides, unmodified and modified with oxidation (M) or acetyl (protein N-terminal)
were used for protein quantification. Contaminant sequences were included in the search and revert
sequences were used for decoy search. The generated results file was further analyzed with Perseus
version 1.6.6.0 [53]. Proteins identified in all samples in both groups were included together with
proteins identified in all samples in one group but were below detection limit in all samples in the
other group, since these are of high interest as putative biomarkers. Differentially expressed proteins
were defined as proteins that were 2-fold or more differentially expressed with a significance level at
p < 0.05 (t-test).
4.6. Western Blotting
Western blotting was done essentially as previously described [49]. In short, 30 µg of total
protein from cell lines or 10 µg of total protein from tissue was loaded in each lane, separated by
electrophoresis and blotted onto nitrocellulose Hybond-C Extra membranes. We used the total protein
level for normalization of the blots and abstained from using household proteins. This was based
on our previous experience that GAPDH and actin are differentially expressed in lymphoma tumor
biopsies [49]. Furthermore, Hu and coworkers [54] have shown that seven commonly used household
proteins change expression level in CRC in particular. Recently, Xu and coworkers [55] showed
that 17 out of 21 classical reference genes were upregulated in CRC at transcript level compared
to normal colonic epithelial tissue. Even among 42 novel potential reference genes some of these
transcripts changed expression level in a subset of the tumors. Thus, the ideal reference gene or
protein is still missing and we found it more reliable to normalize to the total protein as recently
suggested [54]. All primary antibodies were incubated overnight at 4◦C or for one hour at room
temperature. The blots were then incubated with horseradish peroxidase (HRP)-conjugated secondary
antibodies and developed using the enhanced chemiluminescence system. Digital images were taken
using Fujifilm LAS-4000 or LAS-4010 and the corresponding ImageQuant LAS 4000 software (Fuji,
Tokyo, Japan). The images were analyzed by ImageQuant TL, version 7.0. Pixel intensity for each
band was measured and normalized to the background density. The intensities were quantified and
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Mann-Whitney U-test for the cell line studies and Wilcoxon signed rank test for the analyses of patient
tissue were performed to identify significant differences. In the cell line blots, the mean value of
NCM460 pixel intensity was set to 1 as a reference. All intensities were calculated relative to this
reference. In the blots with patient tissue samples, the pixel intensity from the non-involved part of
the colon (N) of each patient was set to 1 and pixel intensity from both the peripheral (P) and central
(C) part of the tumor was calculated from this reference. All values were log2-transformed prior to
visualization by dot plots in Figures 1 and 4.
Primary antibodies: anti-reticulocalbin, anti-calumenin and anti-ERC-55 are all affinity-purified
polyclonal antibodies generated and characterized in our laboratory [34,56,57]. The other antibodies
were purchased from commercial suppliers: anti-RBP (ab31106, Abcam PLC, Cambridge, UK),
anti-SET (NBP1-33713, Novus Biologicals, LLC, Centennial, CO, USA), anti-S100A4 (HPA007973,
Atlas Antibodies AB, Bromma, Sweden), anti-S100A6 (ab11181, Abcam) and anti-endoplasmin
(HPA008424, Atlas Antibodies). Secondary HRP-conjugated antibodies: rabbit anti-mouse PO260 HRP,
swine anti-rabbit PO217 HRP and rabbit anti-goat PO449 HRP were purchased from Dako Denmark
A/S (Glostrup, Denmark).
4.7. Bioinformatics
All MS identified proteins from 2D-PAGE analysis with two or more peptides (Table 2) together with
S100A6, calumenin, and reticulocalbin were uploaded to STRING v11.0 (https://string-db.org/) [28]
using the Uniprot entry names. For the bioinformatic analysis of proteins identified with LFQ
LC–MS/MS all 901 proteins listed in supplementary Table S1 were uploaded and STRING recognized
899. In the STRING analysis we focused on the Gene Ontology aspects, Molecular Function and
Cellular Component as well as pathways identified from the Reactome pathway database [58].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/10/3466/
s1. Table S1: The differentially expressed proteins. Figure S1: Bioinformatic analysis of differentially expressed
proteins in HCT 116 cells versus NCM460 cells obtained by LFQ LC-MS/MS.
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